Codis Strengthens its Market Position with Nottingham Facility Acquisition

Codis Expands European Spray Dry Network with Nottingham Facility Acquisition

In a significant move set to redefine its position in the pharmaceutical manufacturing sector, Codis, a global leader in contract development and manufacturing (CDMO), has successfully acquired Catalent's Nottingham facility, marking a major expansion of its European operations. This strategic acquisition aims to bolster Codis' integrated spray drying offerings, significantly enhancing its capabilities in spray drying and the production of amorphous solid dispersions (ASDs).

The Nottingham facility, with its rich history of over 20 years in formulation and clinical supply expertise, is poised to bring substantial value to Codis. This acquisition allows Codis to combine Nottingham's specialized solutions with its ongoing operations in Haverhill, UK, effectively creating a seamless pathway from development through to commercial manufacturing. The collaboration promises to deliver robust support for customers, ensuring that they can bring their products to market with increased speed and reduced risk.

Nicolas Fortin, CEO of Codis, expressed his enthusiasm about this acquisition, stating, “This is an exciting milestone for Codis. We are delighted to welcome the Nottingham team into the Codis family. Their scientific strength and long track record of delivering high-quality solutions make them an exceptional addition to our organization.” Fortin emphasized the unique integration that the combined capabilities of Nottingham and Haverhill will provide, promoting efficiency and continuity throughout the manufacturing process.

Under the leadership of Matthew Streeter, the newly appointed General Manager of the Nottingham site, the facility is set to become a key player in Codis’ ambitious growth strategy. Streeter remarked, “My team and I are excited to join Codis and look forward to playing a big part in building an expanded, strategically important service at the company.” This renewed focus aims to enhance Codis’ portfolio of bioavailability solutions, facilitating a smooth transition from initial development phases all the way to clinical supply and final dose forms.

The acquisition is particularly timely, complementing Codis’ existing large-scale commercial spray drying facility in Haverhill, which is on the verge of undergoing significant expansion. A new GEA Pharma-SD® PSD-4 commercial spray dryer is expected to be validated in 2027, further enhancing the capabilities available to Codis customers. This investment demonstrates Codis’ commitment to staying at the forefront of technological advancements in the industry.

Steve Facer, Senior Vice President of Sales and Marketing at Codis, highlighted the differentiated offerings that this acquisition will bring to the market. He stated, “Codis now offers the most compelling spray dry capability in Europe. With our development expertise, integrated analytical support, and commercial-scale spray drying all bundled under one organization and quality system, our customers are provided with the fastest and lowest-risk path to unlock a molecule’s full potential.” This assurance of quality and efficiency is set to resonate well with clients who are navigating the challenges presented by poorly soluble molecules.

About Codis:
Codis operates as a leading CDMO focused on commercial spray drying, amorphous solid dispersions, and particle engineering for the pharmaceutical, consumer health, and nutraceutical sectors. With over 400,000 square feet of cGMP facilities situated in St. Louis, Missouri, Seymour, Indiana, and both Nottingham and Haverhill in the UK, Codis combines decades of regulatory expertise and development strength under one cohesive brand. The organization is dedicated to advancing the medicine landscape by providing innovative and effective manufacturing solutions tailored to meet diverse client needs. For more information about Codis and its services, please visit www.codis.com.